

BioSig Technologies, Inc.

10:06 15 Sep 2020

BioSig Technologies says scientific abstract concludes that its PURE EP System is able to produce reliable and high-quality signals when compared to the available systems

BioSig Technologies, Inc. (NASDAQ:BSGM) has revealed that scientific abstract has concluded that its PURE EP System is able to produce reliable and high-quality signals when compared to the available standard of care systems.

The abstract and poster, entitled 'A novel cardiac signal processing system for electrophysiology procedures: early insights from the PURE EP 2.0 study', will be available electronically from August 30 at the ESC Congress 2020 - The Digital Experience.

The medical technology company is developing a proprietary biomedical signal processing platform, the PURE EP System designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals. PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

READ: BioSig Technologies installs PURE EP System at Massachusetts General Hospital as part of clinical study

The group said the abstract is co-authored by Carola Gianni, M.D., Amin Al-Ahmad, M.D., Shane M. Bailey, M.D., G. Joseph Gallinghouse, M.D., Rodney P. Horton, M.D. and Andrea Natale, M.D. of the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center in Austin, TX. The independent, blinded reviewers were Bradley P. Knight, M.D. (Northwestern University), Wendy Tzou, M.D. (University of Colorado), and Pasquale Santangeli, M.D. (University of Pennsylvania).

According to the abstract, identical electrocardiographic and intracardiac signal data were recorded during 15 atrial fibrillation ablation procedures from the PURE EP System, the signal recording system, and the 3D mapping system. The collected signals underwent blinded, controlled evaluation by three independent electrophysiologists to determine whether the PURE EP signals are a viable alternative to conventional sources and if it provides additional or clearer diagnostic information.


The reviewers were asked to record the quality of each signal sample on a scale of 1-10 and select a rationale for their rating in a dropdown menu. Based on the ratings for each pair of signals, a cumulative total of 29 PURE EP signals out of 34 (85.3%) were rated as statistically equivalent or better for this dataset. In 35.5% of samples, the reviewers selected PURE EP data because "more signal components were visible."

"BioSig Technologies is very pleased to see some of the early results from the PURE EP study shared during ESC 2020. We greatly appreciate the scientific collaboration with the team at TCAI and the independent EP reviewers. The PURE EP study is on-going, and we look forward to sharing multi-center data with the EP community in the coming

Price: 4.99

Market Cap: \$148.72 m

1 Year Share Price Graph



October 2019 April 2020 October 2020

Share Information

Code: BSGM

Listing: NASDAQ

52 week High Low
12.43 2.37

Sector: Medical technology & services

Website: www.biosigtech.com

Company Synopsis:

BioSig Technologies, Inc. , a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals.

action@proactiveinvestors.com

months," Julie Stephenson, VP of Clinical Affairs at BioSig Technologies said in a statement.

The European Society of Cardiology (ESC) is an independent, non-profit organization whose members represents more than 95,000 men and women in the field of cardiology from Europe, the Mediterranean Basin, and far beyond. Due to the COVID-19 pandemic, the government in the Netherlands has banned all meetings until September 1, so as Amsterdam was to be the host city, it is no longer possible for ESC Congress to take place as planned, instead the online event is available at no charge, although pre-registration is required via [here](#).

Contact the author at jon.hopkins@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of BioSig Technologies, Inc. named herein, including the promotion by the Company of BioSig Technologies, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).